IMMUNOHISTOCHEMISTRY, CD 30

What this test checks

Detects CD30, expressed on Reed-Sternberg cells in Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). Crucial for diagnosing these specific lymphomas and determining eligibility for CD30-targeted therapy (brentuximab).

Why do people get this test?

CD30-positive lymphomas (Hodgkin lymphoma and ALCL) can now be treated with brentuximab vedotin — a targeted antibody-drug conjugate. CD30 testing determines eligibility for this highly effective therapy.

When you should consider this test

• When Hodgkin lymphoma or ALCL is suspected
• When determining eligibility for brentuximab vedotin targeted therapy
• As part of lymphoma diagnostic and treatment-planning panel

How to prepare

No preparation needed — performed on biopsy or surgical tissue.